Becton, Dickinson and Company (BDX)

NYSE - Nasdaq Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

259.14

+0.58

(+0.22%)

As of 02:36PM EDT. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Price Crosses Moving Average

View all chart patterns

Performance Outlook

Previous Close	258.56
Open	258.95
Bid	259.06 x 800
Ask	259.28 x 900
Day's Range	258.81 - 262.45
52 Week Range	229.40 - 277.29
Volume	359,754
Avg. Volume	990,162

Market Cap	73.905B
Beta (5Y Monthly)	0.61
PE Ratio (TTM)	39.38
EPS (TTM)	6.58
Earnings Date	Nov 02, 2022 - Nov 07, 2022
Forward Dividend & Yield	3.48 (1.35%)
Ex-Dividend Date	Sep 08, 2022
1y Target Est	274.55

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

-24% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for BDX

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Becton, Dickinson and Company
Analyst Report: Becton, Dickinson and CompanyBecton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Rating
Fair Value
Economic Moat
7 days agoMorningstar

All

Insider Monkey
Here’s Why ClearBridge Investments Acquired Shares in Becton, Dickinson and Company (BDX)
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Value Strategy” second quarter 2022 investor letter. A copy of the letter can be downloaded here. In the second quarter, the strategy underperformed its Russell 1000 Value benchmark Index. The second quarter was highly volatile due to changes in interest rates, fears of recession, and […]
PR Newswire
BD, Labcorp Collaborate to Develop Flow Cytometry-Based Companion Diagnostics for Matching Patients with Treatments
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration agreement with Labcorp (NYSE: LH), a leading global life sciences company, creating a framework to develop, manufacture, market and commercialize flow cytometry-based companion diagnostics (CDx) intended to match patients with life-changing treatments for cancer and other diseases.
- Enable Injections Enhances Board with Addition of John DeFord, Ph.D.
  PR Newswire
- Here’s Why ClearBridge Investments Acquired Shares in Becton, Dickinson and Company (BDX)
  Insider Monkey
PR Newswire
BD Announces Tender Offers for Outstanding Debt Securities
Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced that it has commenced tender offers to purchase for cash the debt securities issued by the Company listed in the table below (collectively, the "Securities" and each a "series").
- Freddie Mac Updates Results of Tender Offer for Certain STACR Debt Notes
  GlobeNewswire
- Tortoise Announces Tender Offers for its Closed-End Funds
  ACCESSWIRE